Role of gastrograffin in adhesive bowel obstruction after unsuccessful conservative treatment: a prospective evaluation

Suresh Maharjan; Kishor Manandhar; Binita Singh; Niliza Shakya; Om P. Patel

doi:10.18203/2349-2902.isj20243021

Authors

Suresh Maharjan Department of Surgery, National Academy of Medical sciences, Bir Hospital, Kathmandu, Nepal
Kishor Manandhar Department of Surgery, National Academy of Medical sciences, Bir Hospital, Kathmandu, Nepal
Binita Singh Department of Health Science, Child Health Division, Kathmandu, Nepal
Niliza Shakya Department of Surgery, National Academy of Medical sciences, Bir Hospital, Kathmandu, Nepal
Om P. Patel Department of Surgery, Armed Police Force Hospital, Chandragiri Municipality, Nepal

DOI:

https://doi.org/10.18203/2349-2902.isj20243021

Keywords:

Adhesive small bowel obstruction, Gastrograffin, Small bowel obstruction, Laparotomy

Abstract

Background: Water soluble gastrograffin (GG) administration via nasogastric (NG) tube has shown to resolve the obstructive features and reduced the need for surgery and reduced hospital stay in the patients presenting with adhesive small bowel obstructions (ASBOs). Thus the use of GG in patients who did not improve after 48 hours of conservative treatment was found to be very useful in the management of ASBOs.

Methods: 77 patients presenting with the features of ASBOs in Department of General Surgery, Bir Hospital were included in the study which took place from July 2021 to April 2022. Those patients who presented with the signs of strangulation, peritonitis, complete obstruction and clinical signs of large bowel obstruction were excluded from the study.

Results: The mean time at which the symptoms of abdominal pain resolved was 17.45 hours, 28.5 hours and 23.06 hours in patients improved with conservative management, with GG and who undergone surgery respectively. The mean time for passage of flatus was 57.42 hours in patients treated with GG. The mean time in which the patients passed stool was 36.92 hours, 66 hours and 74.8 hours in patients treated with conservative treatment, GG and operated respectively. It took 50.81 hours, 81.68 and 95.4 hours for improvement with conservative management, GG and surgery respectively.

Conclusions: The administration of GG in ASBOs after the failure of the initial 48 hours conservative management of ASBOs reduced the need for operative procedures and number of hospital days as most of them did not require surgery.

Metrics

Metrics Loading ...

References

Bevan PG. Bevan PG. Adhesive obstruction. Ann R Coll Surg Engl. 1984;66(3):164.

McEntee G, Pender D, Mulvin D, McCullough M, Naeeder S, Farah S, et al. Current spectrum of intestinal obstruction. Br J Surg. 2005;74(11):976-80.

Richards WO, Williams LF. Richards WO, Williams Jr LF. Obstruction of the large and small intestine. Surg Clin North Am. 1988;68(2):355-76.

Shahid MA, Bhatta P, Raya A, Rai BK. Shahid MA, Bhatta P, et al. Therapeutic Role of Gastrograffin in Adhesive Small Bowel Obstruction After Unsuccessful Conservative Treatment. Med Phoenix. 2020;5(1):26-31.

Roadley G, Cranshaw I, Young M, Hill AG. Roadley G, Cranshaw I, et al. Role of Gastrografin in assigning patients to a non‐operative course in adhesive small bowel obstruction. ANZ J Surg. 2004;74(10):830-2.

Riemann JF, Bonvoisin S, Editors. Menzies D, Ellis H. Intestinal obstruction from adhesions--how big is the problem? Ann R Coll Surg Engl. 1990;72(1):60.

Choi HK, Chu KW, Law WL. Choi HK, Chu KW, Law WL. Therapeutic value of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment: a prospective randomized trial. Ann Surg. 2002;236(1):1.

Kapoor S, Jain G, Sewkani A, Sharma S, Patel K, Varshney S, et al. Prospective evaluation of oral gastrografin in postoperative small bowel obstruction. J Surg Res. 2006;131(2):256-60.

Schein M, Assalia A. Assalia A, Schein M, Kopelman D, Hirshberg A, et al. Therapeutic effect of oral Gastrografin in adhesive, partial small-bowel obstruction: a prospective randomized trial. Surgery. 1994;115(4):433-7.

Baghdadi YM, Choudhry AJ, Goussous N, Khasawneh MA, Polites SF, Zielinski MD. Long-term outcomes of gastrografin in small bowel obstruction. J Surg Res. 2016;202(1):43-8.

Shingla R, Singh B, Kumar A. Role of gastrografin contrast study in intestinal obstruction. Int J Anat Radiol Surg. 2017;6:S001-5.

Di Saverio S, Coccolini F, Galati M, Smerieri N, Biffl WL, Ansaloni L, et al. Bologna guidelines for diagnosis and management of adhesive small bowel obstruction (ASBO): 2013 update of the evidence-based guidelines from the world society of emergency surgery ASBO working group. World J Emerg Surg. 2013;8(1):1-4.

Trésallet C, Lebreton N, Royer B, Leyre P, Godiris-Petit G, Menegaux F. Improving the management of acute adhesive small bowel obstruction with CT-scan and water-soluble contrast medium: a prospective study. Dis Colon Rectum. 2009;52(11):1869-76.

Zielinski MD, Haddad NN, Cullinane DC, Inaba K, Yeh DD, Wydo S, et al. Multi-institutional, prospective, observational study comparing the Gastrografin challenge versus standard treatment in adhesive small bowel obstruction. J Trauma Acute Care Surg. 2017;83(1):47-54.

Choi HK, Law WL, Ho JW, Chu KW. Value of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment: a prospective evaluation. World J Gastroenterol. 2005;11(24):3742.

López LM, Serra-Aracil X, Bayo HL, Soto SN. Use of Gastrografin® in the management of adhesion intestinal obstruction. Cirugía Española (English Edition). 2013;91(6):384-8.

Gupta R, Agrawal C, Pathania O, Yadav R, Shah P. Gupta RK, et al. A Prospective Study on the Gastrografin Contrast Radiology in the Management of Small Bowel Obstruction. Arch Clin Exp Surg ACES. 2013;2(1):24.

Hany AE, Osman S, Salah A, Yahya M. Clinical Values of Orally Administrated Gastrografin in Management of Adhesive Small Bowel Obstruction. Med J Cairo Univ. 2018;86(6):1171-7.

Safamanesh S, Pazouki A, Tamannaie Z, Mohammadalipour B, Ramezani K, Hajnasrollah E, et al. Evaluation of gastrografin therapeutic role in the management of small bowel obstruction. J Minim Invasive Surg Sci. 2013;1(3):90-3.

Abbas S, Bissett I, Parry B. Oral water soluble contrast for the management of adhesive small bowel obstruction. Cochrane Database Syst Rev. 2007;2007(3):CD004651.

Feigin E, Seror D, Szold A, Carmon M, Allweis TM, Nissan A, et al. Water-soluble contrast material has no therapeutic effect on postoperative small-bowel obstruction: results of a prospective, randomized clinical trial. Am J Surg. 1996;171(2):227-9.

Biondo S, Pares D, Mora L, MartíRagué J, Kreisler E, Jaurrieta E. Randomized clinical study of Gastrografin® administration in patients with adhesive small bowel obstruction. J Br Surg. 2003;90(5):542-6.

AI Wadani H, Al Awad NI, Hassan KA, Zakaria HM, Al MulhimAA, Alaqeel FO. Role of water soluble contrast agents in assigning patients to a non-operative course in adhesive small bowel obstruction. Oman Med J. 2011;26(6):454.

Bueno-Lledó J, Barber S, Vaqué J, Frasson M, Garcia-Granero E, Juan-Burgueño M. Adhesive small bowel obstruction: predictive factors of lack of response in conservative management with gastrografin. Digest Surg. 2016;33(1):26-32.

Farid M, Fikry A, El Nakeeb A, Fouda E, Elmetwally T, Yousef M, et al. Clinical impacts of oral gastrografin follow-through in adhesive small bowel obstruction (SBO). J Surg Res. 2010;162(2):170-6.

Weiss A, Sood D, Greenway SE, Tomassi M. Value of gastrografin in adhesive small bowel obstruction. Langenbeck’s Arch Surg. 2017;402(8):1233-9.

Haule C, Ongom PA, Kimuli T. Efficacy of Gastrografin® compared with standard conservative treatment in management of adhesive small bowel obstruction at Mulago National Referral Hospital. J Clin Trials. 2013;3(4).